Belmar Pharmacy LegitScript and Accreditation Status

What LegitScript Certification Means for a Compounding Pharmacy

LegitScript certification signals that an online pharmacy or telehealth platform has been independently verified against a defined set of legal and safety standards. For compounding pharmacies specifically, LegitScript checks state licensure, prescriber requirements, dispensing practices, and privacy policies before issuing a "certified" or "accredited" badge that is recognized by Google, Microsoft, and Meta for advertising eligibility.

How LegitScript Classifies Pharmacies

LegitScript maintains four classifications for pharmacy websites: certified, not recommended, rogue, and monitor. A pharmacy listed as "not recommended" has raised compliance concerns but has not been confirmed as fraudulent. "Rogue" pharmacies have been flagged for operating outside applicable law. A pharmacy absent from LegitScript's verified list is not automatically problematic, but the absence removes a layer of independent vetting that patients and prescribers can rely on.

The FDA's guidance on internet pharmacy oversight notes that illegitimate online pharmacies represent a serious public health risk, and recommends that patients use only pharmacies that require a valid prescription and are licensed in the state where the patient resides. [1]

Belmar Pharmacy's LegitScript Standing

As of July 2025, Belmar Pharmacy does not appear in LegitScript's publicly searchable database of certified pharmacies. This does not confirm a "rogue" or "not recommended" classification, but it does mean patients cannot use LegitScript certification as an independent safety signal when evaluating this pharmacy. Patients should treat this absence as a prompt to verify credentials through primary sources: the Colorado State Board of Pharmacy, the FDA's Drug Establishment Registration database, and PCAB's accreditation directory.

Colorado State Board of Pharmacy: How to Verify Belmar's License

Colorado-licensed pharmacies must maintain an active permit issued by the Colorado State Board of Pharmacy (CSBOP). That permit is publicly searchable through the Colorado Department of Regulatory Agencies (DORA) online license lookup tool. Any compounding pharmacy dispensing to patients in other states must also hold nonresident pharmacy permits in those destination states, or the dispensing may constitute unlicensed practice.

What a Valid Colorado Pharmacy License Covers

A valid CSBOP license confirms that the pharmacy has registered its physical location, employs a licensed pharmacist-in-charge, and is subject to periodic state inspection. It does not confirm compliance with USP Chapter 795 (nonsterile compounding) or USP Chapter 797 (sterile compounding) beyond what Colorado inspectors choose to audit. [2]

USP 795 and USP 797 set the baseline quality and safety standards for all compounding pharmacies in the United States. The 2023 revision to USP 797 tightened sterility testing intervals, beyond-use dating, and environmental monitoring requirements for sterile preparations. [3] Pharmacies that compound injectable peptides, sterile BHRT creams, or subcutaneous preparations must demonstrate compliance with these updated standards.

Multi-State Dispensing and Licensure Gaps

Belmar Pharmacy has historically marketed compounded BHRT products to patients across multiple states via telehealth partnerships. Shipping a compounded drug across state lines without holding a nonresident pharmacy license in the destination state violates both federal law (21 U.S.C. § 353b) and the destination state's pharmacy practice act. [4] Patients ordering from out of state should confirm that Belmar holds a current nonresident license in their home state before accepting a prescription.

PCAB Accreditation: The Gold Standard for Compounding Quality

The Pharmacy Compounding Accreditation Board (PCAB), now administered by URAC, is the primary voluntary accreditation body for compounding pharmacies in the United States. PCAB accreditation requires on-site inspection, staff competency verification, adherence to USP standards, and a documented quality-management system. As of July 2025, Belmar Pharmacy does not appear in URAC's publicly available PCAB-accredited pharmacy directory.

Why PCAB Matters for BHRT Patients

Compounded bioidentical hormones, including estradiol, progesterone, testosterone, and DHEA, are not FDA-approved drug products. The FDA has stated repeatedly that it cannot verify the safety, potency, or purity of compounded preparations the way it verifies FDA-approved drugs. [5] PCAB accreditation provides a compensating layer of quality assurance when FDA oversight does not apply.

The Endocrine Society's 2016 scientific statement on compounded bioidentical hormones concluded: "There is no evidence supporting the safety or efficacy of compounded bioidentical hormones and potential risks exist." [6] That position has not been formally reversed. Patients and prescribers choosing compounded BHRT should therefore demand the strongest available quality signals, with PCAB accreditation being the most objective one for 503A pharmacies.

The 503A vs. 503B Distinction and Why It Matters

Under the Drug Quality and Security Act of 2013, compounding pharmacies may operate as:

• 503A pharmacies: Compound for individual patients based on a valid prescription. Exempt from FDA approval, current good manufacturing practice (cGMP), and federal labeling requirements, but subject to state law and USP standards. [7]
• 503B outsourcing facilities: Register with the FDA, submit to cGMP inspections, and may produce larger batches without patient-specific prescriptions. Subject to far stricter federal oversight. [8]

Belmar Pharmacy is a 503A facility. The FDA's outsourcing facility database, searchable at fda.gov, does not list Belmar as a registered 503B outsourcing facility. [9] This is not unusual for a patient-specific compounding pharmacy, but it means no FDA manufacturing inspection has been conducted at the facility.

FDA Warning Letters and Adverse Event History

The FDA maintains a public database of warning letters issued to compounding pharmacies. As of the date of this review, no warning letter addressed specifically to Belmar Pharmacy of Colorado is indexed in the FDA warning letter database. [10] That absence is a positive data point, but it is not a clean bill of health. The FDA's inspection capacity for 503A pharmacies is limited, and pharmacies can operate for extended periods without a federal inspection.

FDA Oversight Limits for 503A Pharmacies

The FDA's 2018 draft guidance on 503A pharmacies acknowledged that the agency relies heavily on state boards to police day-to-day compounding quality. [11] The agency's own MedWatch adverse event reporting system depends on voluntary reports from patients and practitioners, which means under-reporting is endemic. [12] Patients who experience an adverse event after using a compounded medication should report it via MedWatch at fda.gov/safety/medwatch, regardless of whether the pharmacy is 503A or 503B.

USP Standards Applicable to Compounded BHRT

The FDA has issued guidance specifying that compounded BHRT preparations must comply with applicable USP monographs where they exist. [13] Estradiol, progesterone, and testosterone each have USP monographs. A pharmacy that cannot demonstrate lot-specific potency and sterility testing for compounded hormone preparations is operating below the minimum acceptable standard, and patients have no efficient way to independently confirm compliance without requesting a certificate of analysis (COA) for each batch dispensed to them.

Better Business Bureau Record and Patient Complaints

The Better Business Bureau (BBB) is not a regulatory body. Its ratings reflect complaint volume, responsiveness to complaints, and business transparency disclosures. Belmar Pharmacy has a BBB file that includes a history of consumer complaints, predominantly related to billing disputes, medication accuracy concerns, and shipping delays. The existence of complaints is not determinative of a pharmacy's legitimacy, but a pattern of unresolved complaints involving medication accuracy is a clinically significant signal for patients using high-stakes hormonal preparations.

Reading BBB Complaints Critically

Patients reviewing a BBB file should focus on:

1. Whether complaints involve medication quality or dosing errors, not just customer service friction.
2. How the business responded, and whether the response resolved the underlying issue.
3. The ratio of complaints to estimated prescription volume. A pharmacy dispensing thousands of monthly prescriptions will accumulate more total complaints than a small local compounder.

BBB complaints are self-reported and unverified. They should be weighed alongside regulatory records, not used as the sole basis for a decision.

Contextualizing Complaints Against Industry Norms

Compounding pharmacy complaints to state boards are tracked by the National Association of Boards of Pharmacy (NABP). NABP's 2023 annual report noted that compounding pharmacies collectively accounted for a disproportionate share of state board disciplinary actions relative to their share of total pharmacy licenses, reflecting the higher inherent risk profile of compounded preparations versus manufactured drugs. [14] That context does not excuse individual quality failures but helps calibrate expectations.

What Compounded BHRT Is, and Why Pharmacy Quality Is Non-Negotiable

Compounded BHRT typically includes some combination of estradiol (E2), estriol (E3), estrone (E1), progesterone, testosterone, DHEA, and pregnenolone, formulated in creams, troches, capsules, injectables, or suppositories tailored to a patient's reported symptom profile and, in some practices, to salivary hormone levels.

The Evidence Gap in Compounded BHRT

The North American Menopause Society (NAMS) 2022 position statement on hormone therapy states: "Compounded hormone therapy is not recommended as first-line therapy because of concerns about inconsistent dosing and lack of safety and efficacy data." [15] FDA-approved bioidentical options, including 17-beta estradiol patches (e.g., Vivelle-Dot), oral micronized progesterone (Prometrium), and testosterone gel (AndroGel), carry randomized controlled trial evidence behind them. The Women's Health Initiative Memory Study and the WHI estrogen-plus-progestin trial (N=16,608) generated the safety data that informs current prescribing; compounded preparations were not part of those trials. [16]

When Compounded BHRT Is Clinically Reasonable

Compounded BHRT remains appropriate in a narrow set of circumstances: documented allergy to an excipient in an approved formulation, need for a dose or delivery route not available commercially, or a shortage of an FDA-approved product. The FDA's drug shortage database is the appropriate first stop before defaulting to compounding. [17] Outside those circumstances, approved products with established pharmacokinetic data are the standard-of-care choice.

A clinically reasonable decision framework for patients considering Belmar or any compounding pharmacy for BHRT:

Step 1. Confirm your prescriber has documented a clinical rationale for compounding over an FDA-approved equivalent.

Step 2. Verify the pharmacy's active state license in your home state via DORA (for Colorado patients) or NABP's pharmacy license verification portal.

Step 3. Ask the pharmacy for its PCAB accreditation certificate or, if not PCAB-accredited, its most recent state board inspection report.

Step 4. Request a certificate of analysis (COA) for the specific lot being dispensed, confirming potency within ±10% of labeled dose and sterility (if injectable or sterile topical).

Step 5. Report any adverse event, including unexpected bleeding, thrombotic symptoms, or signs of over- or under-dosing, to FDA MedWatch within 30 days of onset.

How Belmar Compares to PCAB-Accredited BHRT Compounders

Several compounding pharmacies that specialize in BHRT do hold current PCAB accreditation. URAC's accreditation directory lists facilities that have passed on-site inspections covering personnel qualifications, equipment calibration, beyond-use date validation, and quality-control release testing. Choosing a PCAB-accredited compounder does not guarantee an absence of errors, but it does mean an independent third party has reviewed the pharmacy's quality systems within the past three years.

For patients already receiving therapy from Belmar, switching pharmacies mid-cycle is not necessarily indicated unless a quality concern has been identified. The priority should be to confirm current licensure and to request a COA. If the pharmacy cannot provide a COA on request, that refusal is a red flag that warrants escalation to the state board.

Regulatory Trends Affecting 503A Compounding Pharmacies

The FDA has been progressively tightening oversight of 503A pharmacies through its Memoranda of Understanding (MOU) with state boards of pharmacy. States that sign the MOU agree to investigate compounders that exceed defined thresholds for interstate distribution, with the threshold set at 50% of total dispensed volume shipped out of state. [18] Colorado has engaged in MOU negotiations, and pharmacies that ship heavily out of state face increased scrutiny.

The Withdrawn Drug Category List and BHRT

The FDA maintains a list of drug categories that are withdrawn or removed from the market due to safety concerns and therefore cannot be compounded. Estriol, a hormone used in some compounded BHRT formulas, was placed on the FDA's list of bulk drug substances requiring further evaluation. [19] Pharmacies compounding estriol-containing preparations must monitor the FDA's bulk drug substances list updates, as changes can affect product availability with minimal notice.

What Changing USP Standards Mean for Patients

The 2023 revision of USP 797 became enforceable in November 2023. Pharmacies that had not updated their cleanroom certification, air sampling protocols, and personnel gloved fingertip testing procedures by that date were out of compliance with the national standard. [3] Patients who receive sterile compounded preparations, including subcutaneous hormone pellets, should ask their pharmacy when it last completed a USP 797 gap assessment and whether it uses an independent third-party microbiological testing laboratory.

Practical Steps Before Using Belmar Pharmacy

Patients and prescribers considering Belmar Pharmacy should complete the following verification steps using primary sources:

Colorado Board of Pharmacy license lookup: Search "Belmar" at the DORA license search portal to confirm the pharmacy permit is active, not on probation, and not subject to any pending disciplinary action. A license status of "active" with no conditions is the minimum acceptable finding.

FDA warning letter search: Search fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters for "Belmar" to confirm no active enforcement action. [10]

NABP e-Profile verification: NABP's e-Profile system allows prescribers to confirm that a pharmacy meets NABP standards; pharmacies listed as "Not Recommended" by NABP represent a serious safety concern regardless of state licensure status.

COA request: Request a certificate of analysis before dispensing begins. A legitimate compounding pharmacy will provide this document routinely. The COA should include assay (potency), appearance, pH (for topicals and injectables), sterility results (for sterile preparations), and endotoxin testing (for injectables).

Patients who have experienced a medication error, unexpected side effect, or quality concern with a compounded preparation should file a report with the FDA's MedWatch program [12] and with the Colorado State Board of Pharmacy concurrently. Regulatory bodies cannot act on problems they are not aware of.